IR Ingersoll Rand
High-quality aftermarket compounder, but at 82.6 the price already assumes a decade of flawless roll-up execution.
The story
Ingersoll Rand is a roll-up compounder in flow creation and compression: compressors, vacuum, blowers and pumps, with a large installed base that drives high-margin aftermarket parts and service revenue. Its moat is the installed base, mission-critical products and the IRX pricing and operating discipline. It is a mid-life consolidator: organic growth tracks industrial cycles in the low-to-mid single digits, with bolt-on M&A adding several points. Most of the invested capital is acquisition goodwill, so capital efficiency looks worse on the books than in the day-to-day business.
Growth of about 6% (3-4% organic plus bolt-ons) is below the 8.9% 5-year CAGR, which was helped by large deals and post-COVID pricing. The margin stays near the TTM 23% because aftermarket mix and pricing power support it, but I do not push it higher. Sales-to-capital of 1.3 is for incremental capital; the reported 0.54 is weighed down by legacy goodwill. A 10-year horizon fits a durable installed-base franchise with a long M&A runway, even though it is not a 15-year moat.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 23.0% |
| Years to target margin | 3 |
| Sales-to-capital | 1.30 |
| Beta | 1.05 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.4% |
| Terminal WACC | 8.2% |
Valuation bridge
| PV of explicit FCFF | 9.67B |
| PV of terminal value | 13.29B |
| Equity value | 18.98B |
| ÷ shares → per share | $49.42 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 8.54B | 6.0% | 23.2% | 1.51B | 371.64M | 1.14B | 1.05B |
| 2 | 9.02B | 5.7% | 23.1% | 1.59B | 372.05M | 1.22B | 1.04B |
| 3 | 9.50B | 5.3% | 23.0% | 1.67B | 370.01M | 1.30B | 1.02B |
| 4 | 9.97B | 5.0% | 23.0% | 1.76B | 365.38M | 1.39B | 1.01B |
| 5 | 10.44B | 4.7% | 23.0% | 1.84B | 358.07M | 1.48B | 987.68M |
| 6 | 10.89B | 4.3% | 23.0% | 1.92B | 348.01M | 1.57B | 966.16M |
| 7 | 11.33B | 4.0% | 23.0% | 1.99B | 335.16M | 1.66B | 941.93M |
| 8 | 11.74B | 3.7% | 23.0% | 2.07B | 319.52M | 1.75B | 915.23M |
| 9 | 12.14B | 3.3% | 23.0% | 2.14B | 301.13M | 1.84B | 886.28M |
| 10 | 12.50B | 3.0% | 23.0% | 2.20B | 280.05M | 1.92B | 855.36M |
Key risks
- Industrial capex downturn hitting compressor and vacuum orders, with China and Europe exposure
- Acquisition overpayment or integration missteps, given the goodwill-heavy balance sheet
- Valuation already prices in years of 7%+ compounding, so a slip in organic growth would compress the multiple
Catalysts
- Recovery in orders and organic growth from reshoring, data center and life-sciences demand
- Continued accretive bolt-on M&A plus buybacks funded by strong free cash flow